Biogen Inc. has announced that its applications for a higher dose regimen of nusinersen, an investigational treatment for spinal muscular atrophy $(SMA)$, are currently under regulatory review in the U.S., Europe, Japan, and other global markets. This new regimen, evaluated in Part C of the DEVOTE trial, involves a more rapid loading of two 50 mg doses 14 days apart, followed by a maintenance dose of 28 mg every four months. The ongoing review aims to assess the potential benefits of this higher dose regimen in improving motor function in individuals with SMA. Biogen remains committed to advancing treatment options in the evolving SMA landscape.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。